Market revenue in 2023 | USD 21.4 million |
Market revenue in 2030 | USD 113.4 million |
Growth rate | 26.9% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.36% in 2023. Horizon Databook has segmented the Mexico cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
According to the International Trade Administration, updated in November 2023, Mexico is the 15thlargest pharmaceutical market globally and the second largest in Latin America after Brazil. In addition, the country’s pharmaceutical market is divided into patented medicines, presenting 51% of the market; generics, presenting 35%; and over-the-counter products, with the remaining 14% by value.
Therefore, the growing pharmaceutical market promotes the demand for advanced therapeutics in Mexico, fueling the demand for cell and gene therapy CDMO. Mexico is attracting international pharmaceutical companies and CDMOs. In addition, the country provides a favorable market environment to attract R&D investment and expansion, stimulating the demand for CDMO.
Most pharmaceutical companies in the country are gradually expanding & modernizing their development and production criteria with the support of CMDO to increase local & international market supply of pharmaceuticals. Furthermore, the country’s generic & biosimilar sector is anticipated to expand in value due to the developing pharmaceutical sector and government initiatives.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Mexico cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account